Platelets express steroidogenic 17β–hydroxysteroid dehydrogenases

Summary

Human blood platelets have important, regulatory functions in diverse hemostatic and pathological disorders, including vascular remodeling, inflammation, and wound repair. Microarray analysis was used to study the molecular basis of essential thrombocythemia, a myeloproliferative disorder with quantitative and qualitative platelet defects associated with cardiovascular and thrombohemorrhagic symptoms, not infrequently neurological. A platelet-expressed gene (HSD17B3) encoding type 3 17β-hydroxysteroid dehydrogenase (previously characterized as a testis-specific enzyme catalyzing the final step in gonadal synthesis of testosterone) was selectively down-regulated in ET platelets, with reciprocal induction of the type 12 enzyme (HSD17B12). Functional 17β-HSD3 activity corresponding to ∼10% of that found in murine testis was demonstrated in normal platelets. The induction of HSD17B12 in ET platelets was unassociated with a concomitant increase in androgen biosynthesis, suggesting distinct functions and/or substrate specificities of the types 3 and 12 enzymes. Application of a molecular assay distinguished ET from normal platelets in 20 consecutive patients (p < 0.0001). These data provide the first evidence that distinct subtypes of steroidogenic 17β−HSDs are functionally present in human blood platelets, and that the expression patterns of HSD17B3 and HSD17B12 are associated with an uncommon platelet disorder manifest by quantitative and qualitative platelet defects.

Keywords

Platelets - hydroxysteroid dehydrogenases - microarray - essential thrombocythemia

• References

• 1 Gnatenko DV, Dunn JJ, McCorkle SR. et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-93.
• 2 Nimer SD. Essential thrombocythemia: Another ‘‘heterogeneous disease” better understood?. Blood 1999; 93: 415-16.
• 3 El-Kassar N, Hetet G, Briere J. et al. Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets. Blood 1997; 89: 128.
• 4 Kondo T, Okabe M, Sanada M. et al. Familial essential thrombocythemia associated with one-base deletion in the 5’-untranslated region of the thrombopoietin gene. Blood 1998; 92: 1091.
• 5 Schafer AI. Thrombocytosis. N Engl J Med 2004; 350: 1211-9.
• 6 Bahou WF, Gnatenko DV. Platelet transcriptome: the application of microarray analysis to platelets. Semin Thromb Hemost 2004; 30: 473-84.
• 7 Iland HJ, Laszlo J, Case DC. Jr. et al. Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. Am J Hematol 1987; 25: 191-201.
• 8 Murphy S, Peterson P, Iland H. et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
• 9 Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. Molecular characterization and evidence for functional coupling to the thrombin receptor. J Clin Invest 1996; 97: 1705-14.
• 10 Heid CA, Stevens J, Livak KJ. et al. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
• 11 Schmidt VA, Nierman WC, Maglott DR. et al. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 1998; 273: 15061-8.
• 12 Tenedini E, Fagioli ME, Vianelli N. et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood 2004; 104: 3126-35.
• 13 Bahou WF, Scudder L, Rubenstein D. et al. A shearrestricted pathway of platelet procoagulant activity is regulated by IQGAP1. J Biol Chem 2004; 279: 22571-7.
• 14 Dhanasekaran SM, Barrette TR, Ghosh D. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6.
• 15 Mehta T, Tanik M, Allison DB. Towards sound epistemological foundations of statistical methods for high-dimensional biology. Nat Genet 2004; 36: 943-7.
• 16 Bahou WF. Protease-activated receptors. Curr Top Dev Biol 2003; 54: 343-69.
• 17 Lane WJ, Dias S, Hattori K. et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000; 96: 4152-9.
• 18 Labrie F, Luu-The V, Labrie C. et al. Endocrine and intracrine journal-titles of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24: 152-82.
• 19 Velculescu V, Zhang L, Vogelstein B. et al. Serial analysis of gene expression. Science 1995; 270: 484-7.
• 20 Strausberg RL, Buetow KH, Emmert-Buck MR. et al. The cancer genome anatomy project: building an annotated gene index. Trends Genet 2000; 16: 103-6.
• 21 Geissler WM, Davis DL, Wu L. et al. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet 1994; 7: 34-9.
• 22 Khetawat G, Faraday N, Nealen ML. et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289-96.
• 23 Nagata Y, Yoshikawa J, Hashimoto A. et al. Proplatelet formation of megakaryocytes is triggered by autocrine- synthesized estradiol. Genes Dev 2003; 17: 2864-9.
• 24 Mindnich R, Moller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004; 218: 7-20.
• 25 Mount S. A catologue of splice junction sequences. Nucl Acid Res 1982; 10: 459-72.
• 26 Mindnich R, Deluca D, Adamski J. Identification and characterization of 17 beta-hydroxysteroid dehydrogenases in the zebrafish, Danio rerio. Mol Cell Endocrinol 2004; 215: 19-30.
• 27 Wattel E, Cambier N, Caulier MT. et al. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 1994; 87: 205-8.
• 28 Sullivan PS, Jackson CW, McDonald TP. Castration decreases thrombocytopoiesis and testosterone restores platelet production in castrated BALB/c mice: evidence that testosterone acts on a bipotential hematopoietic precursor cell. J Lab Clin Med 1995; 125: 326-33.
• 29 Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-7.
• 30 Jones SB, Bylund DB, Rieser CA. et al. alpha 2-Adrenergic receptor binding in human platelets: alterations during the menstrual cycle. Clin Pharmacol Ther 1983; 34: 90-6.
• 31 Pilo R, Aharony D, Raz A. Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism. Thromb Haemost 1981; 46: 538-42.
• 32 Castellsague J, Perez Gutthann S, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf 1998; 18: 117-23.
• 33 Daly E, Vessey MP, Hawkins MM. et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
• 34 Greenberg D, Miao CH, Ho WT. et al. Liver-specific expression of the human factor VII gene. Proc Natl Acad Sci U S A 1995; 92: 12347-51.